(RTTNews) – British drug major AstraZeneca Plc (AZN, AZN.L) said results from an interim analysis of the DUO-O Phase III trial showed treatment with a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumour BRCA mutations.
Patients were treated with Imfinzi in combination with chemotherapy and bevacizumab followed by Imfinzi, Lynparza and bevacizumab as maintenance therapy.
In an additional arm, Imfinzi, chemotherapy plus bevacizumab showed a numerical improvement in PFS versus the control arm but did not reach statistical significance at this interim analysis.
At the time of this planned interim analysis, the overall survival (OS) and other secondary endpoints are immature and will be formally assessed at a subsequent analysis, the company said.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
SeedWorks International, a seed research and development company based in Telangana, has filed its Draft…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…
Stock Check: KFIN Technologies share price declined by almost 11% during Wednesday's trading, marking a…
Stock Market Today: Suzlon Energy share price rebounded almost 6% from its intraday lows in…
Design and technology service provider Tata Elxsi has partnered with drone maker Garuda Aerospace for…
This article is an on-site version of our Unhedged newsletter. Premium subscribers can sign up…